June 12, 2019

Mitchell Warren Elected President of TB Alliance Stakeholders Association, Joins Board of Directors

Global health and HIV/AIDS leader brings extensive experience in advancing critical global health innovations

June 6, 2019

FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis

May 22, 2019

Tuberculosis, Among the Oldest Infectious Diseases, Is Now the World’s Deadliest – It’s Time to Invest in Solutions

TB Alliance Statement from the 72nd World Health Assembly

May 21, 2019

New Research on Drug-Resistant TB Treatment Presented at ATS 2019

Presentations look at an analysis of nonclinical data regarding drug-resistant TB transmission and a clinical case study of a sterile TB granuloma of the brain

May 9, 2019

TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research

New collaboration, supported by U.S. National Institutes of Health, to produce two new clinical stage TB drug candidates

April 29, 2019

Joint Statement on Universal Health Coverage and TB Research

Moving Together to Build a Healthier World

April 25, 2019

A Conversation with Karl Hofmann

Looking back and looking forward with the outgoing president of TB Alliance's Stakeholders Association

April 18, 2019

TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis

Regimens under clinical development include treatment options for drug-resistant forms of TB

March 20, 2019

Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis

This is an important moment to take stock of the milestones achieved in the fight against TB and to spur policymakers and funders to commit the necessary resources to end TB.

March 8, 2019

TB Medicine Pretomanid Enters Regulatory Review Process in the United States